NCT05263570 The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
| NCT ID | NCT05263570 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shengjing Hospital |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-08-01 |
| Primary Completion | 2023-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-08-01 with a primary completion date of 2023-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years or older * HR+/HER2- breast cancer diagnosis based on local standards * Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time * Standard Therapy, determined at the discretion of the investigator, including （TCbHP/THP/EC-THP/AC-THP） * Complete medical history was available * Karnofsky Performance Status (KPS) Scale score ≥ 70 Exclusion Criteria: * Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy) * Pregnant or breast-feeding women * Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer * Those who have stage IV breast cancer
Contact & Investigator
Caigang Liu, PHD
STUDY CHAIR
Shengjing Hospital
Frequently Asked Questions
Who can join the NCT05263570 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05263570 currently recruiting?
Yes, NCT05263570 is actively recruiting participants. Contact the research team at niunannancy@163.com for enrollment information.
Where is the NCT05263570 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT05263570 clinical trial?
NCT05263570 is sponsored by Shengjing Hospital. The principal investigator is Caigang Liu, PHD at Shengjing Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.